CPMV
Mosaic ImmunoEngineering Inc.
Next earnings Aug 17, 2026
$0.67
▲ 0.00%$0.67▲ +87.22%
over 1Y
L $0.31EODHDH $1.05
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+0.0%
1M-8.4%
3M-9.5%
YTD+116.7%
1Y+87.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity -1.00x).
Return on equity 9.2% · latest
Mosaic ImmunoEngineering Inc. shows limited reported revenue, and 9.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$3.50M | -$2.63M | -$1.40M | -$880K | -$616K |
| Net income | -$3.68M | -$2.38M | -$1.01M | -$922K | -$688K |
| Diluted EPS | -$0.55 | -$0.33 | -$0.14 | -$0.13 | -$0.10 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.88M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-14.1%
FCF yield-2.3%
Quality & risk
ROIC (est.)—
Free cash flow-$111K
Total debt—
Net cash$3.62K
Piotroski F-Score2/6
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-15). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-20open ↗NT 10-QPeriod ending 2026-03-312026-05-15open ↗10-KPeriod ending 2025-12-312026-04-15open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗10-QPeriod ending 2025-09-302025-11-19open ↗NT 10-QPeriod ending 2025-09-302025-11-12open ↗10-QPeriod ending 2025-06-302025-08-19open ↗NT 10-QPeriod ending 2025-06-302025-08-12open ↗10-QPeriod ending 2025-03-312025-05-20open ↗NT 10-QPeriod ending 2025-03-312025-05-15open ↗10-KPeriod ending 2024-12-312025-04-15open ↗NT 10-KPeriod ending 2024-12-312025-03-28open ↗
Frequently asked
- Is Mosaic ImmunoEngineering Inc. (CPMV) a buy?
- CPMV currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.00x).
- What is Mosaic ImmunoEngineering Inc.'s quality score?
- CPMV scores 54/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000836564, latest 10-Q filed 2026-05-20) · EODHD · as of 6/22/2026, 11:37:42 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.